Ono Pharmaceutical Co Stock Price To Earning
| OPHLF Stock | USD 12.50 1.20 10.62% |
Ono Pharmaceutical Co fundamentals help investors to digest information that contributes to Ono Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Ono Pink Sheet. The fundamental analysis module provides a way to measure Ono Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ono Pharmaceutical pink sheet.
Ono |
Ono Pharmaceutical Co Company Price To Earning Analysis
Ono Pharmaceutical's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Ono Pharmaceutical Price To Earning | 18.12 X |
Most of Ono Pharmaceutical's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ono Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Ono Pharmaceutical Co has a Price To Earning of 18.12 times. This is 29.88% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The price to earning for all United States stocks is 36.91% higher than that of the company.
Ono Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ono Pharmaceutical's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ono Pharmaceutical could also be used in its relative valuation, which is a method of valuing Ono Pharmaceutical by comparing valuation metrics of similar companies.Ono Pharmaceutical is currently under evaluation in price to earning category among its peers.
Ono Fundamentals
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.35 % | |||
| Current Valuation | 11.13 B | |||
| Shares Outstanding | 488.31 M | |||
| Shares Owned By Insiders | 16.04 % | |||
| Shares Owned By Institutions | 44.41 % | |||
| Price To Earning | 18.12 X | |||
| Price To Book | 2.29 X | |||
| Price To Sales | 0.03 X | |||
| Revenue | 361.36 B | |||
| Gross Profit | 267.85 B | |||
| EBITDA | 123.45 B | |||
| Net Income | 80.52 B | |||
| Cash And Equivalents | 136.18 B | |||
| Cash Per Share | 278.93 X | |||
| Total Debt | 8.65 B | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 4.16 X | |||
| Book Value Per Share | 1,477 X | |||
| Cash Flow From Operations | 61.83 B | |||
| Earnings Per Share | 1.74 X | |||
| Price To Earnings To Growth | 40,587 X | |||
| Number Of Employees | 3.69 K | |||
| Beta | 0.26 | |||
| Market Capitalization | 10.62 B | |||
| Total Asset | 739.2 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 739.2 B | |||
| Last Dividend Paid | 28.0 |
About Ono Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ono Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ono Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ono Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Ono Pink Sheet
Ono Pharmaceutical financial ratios help investors to determine whether Ono Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ono with respect to the benefits of owning Ono Pharmaceutical security.